Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Pertinez

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith Kr Rajoli, Henry Pertinez, Usman Arshad, et al.
British Journal of Clinical Pharmacology|October 21, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith K R Rajoli, Henry Pertinez, Usman Arshad, et al.
The Journal of Antimicrobial Chemotherapy|November 23, 2023
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamstersHelen J Box, Joanne Sharp, Shaun H Pennington, et al.
Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Nature|December 5, 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2Teresa Brevini, Mailis Maes, Gwilym J Webb, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith Kr Rajoli, Henry Pertinez, Usman Arshad, et al.
British Journal of Clinical Pharmacology|October 21, 2020
Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisRajith K R Rajoli, Henry Pertinez, Usman Arshad, et al.
The Journal of Antimicrobial Chemotherapy|November 23, 2023
Lack of antiviral activity of probenecid in vitro and in Syrian golden hamstersHelen J Box, Joanne Sharp, Shaun H Pennington, et al.
Clinical Pharmacology and Therapeutics|March 18, 2026
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib StudyTim Rowland, Richard FitzGerald, Elizabeth Challenger, et al.
Clinical Pharmacology and Therapeutics|October 26, 2021
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2Lauren E Walker, Richard FitzGerald, Geoffrey Saunders, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Nature|December 5, 2022
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2Teresa Brevini, Mailis Maes, Gwilym J Webb, et al.
Pageof 5